September 9, 2020. T-CURX obtains exclusive license from the University of Würzburg, Germany, for a portfolio of 8 patent families, covering novel CAR-T cell technologies and products

T-CURX and University of Würzburg enter into a broad exclusive license agreement for IPR around CAR-T technologies and products developed in the laboratory of Prof. Michael Hudecek, one of the leading European CAR-T cell experts from the University of Würzburg, Germany

Today, T-CURX announces that it has entered into an exclusive licensing agreement with the University of Würzburg, Germany, for a comprehensive portfolio of eight (8) patent families covering several novel CAR-T cell technologies and product opportunities, developed in the laboratory of Prof. Michael Hudecek, one of the co-founders of T-CURX.

Financial terms for the licensing agreement are not disclosed. However, the scope of the license agreement provides T-CURX with a broad IPR basis to commercialize an attractive and competitive pipeline of CAR-T cell therapies in hematologic and solid tumor indications.

The licensed technologies circle around a virus-free gene transfer technology employing Sleeping Beauty transposition, but also includes technologies to enhance the efficacy (T-CURX' Matchmaker technology) and to increase the safety (T-CURX reversible safety-switch) of CAR-T cell therapies developed by T-CURX.